Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report

The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer scre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer Jg. 142; H. 1; S. 44 - 56
Hauptverfasser:	Basu, Partha, Ponti, Antonio, Anttila, Ahti, Ronco, Guglielmo, Senore, Carlo, Vale, Diama Bhadra, Segnan, Nereo, Tomatis, Mariano, Soerjomataram, Isabelle, Primic Žakelj, Maja, Dillner, Joakim, Elfström, Klara Miriam, Lönnberg, Stefan, Sankaranarayanan, Rengaswamy
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.01.2018
Schlagworte:	Age Breast cancer Breast Neoplasms - diagnosis Cancer Cancer screening Cervical cancer Cervix Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - diagnosis Early Detection of Cancer - statistics & numerical data European Union Female Humans Male Mammography Mass Screening - organization & administration Mass Screening - statistics & numerical data Medical research Medical screening Surveys and Questionnaires Uterine Cervical Neoplasms - diagnosis breast cancer cancer screening colorectal cancer European Union cervical cancer
ISSN:	0020-7136, 1097-0215, 1097-0215
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population‐based approach was documented. Among the age‐eligible women, 94.7% were residents of Member States implementing or planning population‐based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll‐out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population‐based screening increased to 72.4% of the age‐eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2–111% for breast cancer, 7.6–105% for cervical cancer and 1.8–127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes. What's new? In 2003 the European Union (EU) Council urged member states to devote greater attention to breast, cervical, and colorectal cancer screening. The second report on progress in this regard was published in 2017. The present manuscript details implementation status, protocol, and organization of screening programs and screening invitation coverage of target populations in member states. The data show that within a decade, the proportion of eligible EU populations having access to breast, cervical, and colorectal cancer screening increased by 5.8, 11.9 and 33.6 percent respectively. Future Council recommendations may need to consider the incorporation of alternative screening strategies.
AbstractList	The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population‐based approach was documented. Among the age‐eligible women, 94.7% were residents of Member States implementing or planning population‐based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll‐out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population‐based screening increased to 72.4% of the age‐eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2–111% for breast cancer, 7.6–105% for cervical cancer and 1.8–127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes. What's new? In 2003 the European Union (EU) Council urged member states to devote greater attention to breast, cervical, and colorectal cancer screening. The second report on progress in this regard was published in 2017. The present manuscript details implementation status, protocol, and organization of screening programs and screening invitation coverage of target populations in member states. The data show that within a decade, the proportion of eligible EU populations having access to breast, cervical, and colorectal cancer screening increased by 5.8, 11.9 and 33.6 percent respectively. Future Council recommendations may need to consider the incorporation of alternative screening strategies. The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring ( N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population‐based approach was documented. Among the age‐eligible women, 94.7% were residents of Member States implementing or planning population‐based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll‐out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population‐based screening increased to 72.4% of the age‐eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2–111% for breast cancer, 7.6–105% for cervical cancer and 1.8–127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes. What's new? In 2003 the European Union (EU) Council urged member states to devote greater attention to breast, cervical, and colorectal cancer screening. The second report on progress in this regard was published in 2017. The present manuscript details implementation status, protocol, and organization of screening programs and screening invitation coverage of target populations in member states. The data show that within a decade, the proportion of eligible EU populations having access to breast, cervical, and colorectal cancer screening increased by 5.8, 11.9 and 33.6 percent respectively. Future Council recommendations may need to consider the incorporation of alternative screening strategies. The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N=80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes. What's new? In 2003 the European Union (EU) Council urged member states to devote greater attention to breast, cervical, and colorectal cancer screening. The second report on progress in this regard was published in 2017. The present manuscript details implementation status, protocol, and organization of screening programs and screening invitation coverage of target populations in member states. The data show that within a decade, the proportion of eligible EU populations having access to breast, cervical, and colorectal cancer screening increased by 5.8, 11.9 and 33.6 percent respectively. Future Council recommendations may need to consider the incorporation of alternative screening strategies. The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes.The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes. The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes.
Author	Lönnberg, Stefan Basu, Partha Dillner, Joakim Anttila, Ahti Soerjomataram, Isabelle Ponti, Antonio Vale, Diama Bhadra Ronco, Guglielmo Segnan, Nereo Tomatis, Mariano Elfström, Klara Miriam Senore, Carlo Sankaranarayanan, Rengaswamy Primic Žakelj, Maja
Author_xml	– sequence: 1 givenname: Partha orcidid: 0000-0003-0124-4050 surname: Basu fullname: Basu, Partha email: BasuP@iarc.fr organization: Screening Group, International Agency for Research on Cancer – sequence: 2 givenname: Antonio surname: Ponti fullname: Ponti, Antonio organization: CPO Piemonte and University Hospital “Città della Salute e della Scienza” – sequence: 3 givenname: Ahti surname: Anttila fullname: Anttila, Ahti organization: Mass Screening Registry/Finnish Cancer Registry – sequence: 4 givenname: Guglielmo orcidid: 0000-0003-3016-1131 surname: Ronco fullname: Ronco, Guglielmo organization: CPO Piemonte and University Hospital “Città della Salute e della Scienza” – sequence: 5 givenname: Carlo surname: Senore fullname: Senore, Carlo organization: CPO Piemonte and University Hospital “Città della Salute e della Scienza” – sequence: 6 givenname: Diama Bhadra orcidid: 0000-0003-2423-0225 surname: Vale fullname: Vale, Diama Bhadra organization: Universidade Estadual de Campinas – sequence: 7 givenname: Nereo surname: Segnan fullname: Segnan, Nereo organization: CPO Piemonte and University Hospital “Città della Salute e della Scienza” – sequence: 8 givenname: Mariano surname: Tomatis fullname: Tomatis, Mariano organization: CPO Piemonte and University Hospital “Città della Salute e della Scienza” – sequence: 9 givenname: Isabelle surname: Soerjomataram fullname: Soerjomataram, Isabelle organization: Section of Cancer Surveillance, International Agency for Research on Cancer – sequence: 10 givenname: Maja surname: Primic Žakelj fullname: Primic Žakelj, Maja organization: Institute of Oncology Ljubljana – sequence: 11 givenname: Joakim surname: Dillner fullname: Dillner, Joakim organization: Swedish Cervical Screening Registry – sequence: 12 givenname: Klara Miriam surname: Elfström fullname: Elfström, Klara Miriam organization: Regionalt cancercentrum Stockholm‐Gotland – sequence: 13 givenname: Stefan surname: Lönnberg fullname: Lönnberg, Stefan organization: Cancer Registry of Norway, Oslo, Norway; Finnish Cancer Registry – sequence: 14 givenname: Rengaswamy surname: Sankaranarayanan fullname: Sankaranarayanan, Rengaswamy organization: Screening Group, International Agency for Research on Cancer
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28940326$$D View this record in MEDLINE/PubMed
BookMark	eNp1kc1O3DAURq2Kqgw_C16gssSGLgLXceJMlmhECxUVC2BtOZ5r8CixUzsRglUfotu-XJ-kHjK0EiorS9fnfLa-u0O2nHdIyAGDYwaQn9iVPuYMCv6OzBjUVQY5K7fILN1BVjEutslOjCsAxkooPpDtfF4XwHMxI7-uBzWMkXpDbde32KFLA-sdVW5JfbhTzj5Ng4Ro5TQGGnVAdNbdUevozT3SszH4HpWjt25NfsOuSdg6GuPvHz-vx65T4ZEGjGM7RGqC7-iQvIjap2f-6v-CA_Y-DHvkvVFtxP3NuUtuP5_dLM6zy6svF4vTy0wXUPHMlGUDqQC-rIUydalMUxkzb3ittSmEypUSjVBLznLgeq6VKMEUSje1EJhEvkuOptw--O8jxkF2NmpsW-XQj1GyusgrKJjIE3r4Cl35Mbj0u0QJqMW8YiJRHzfU2HS4lH2w6wbkS_EJOJkAHXyMAY3Udip-CMq2koFcr1am1crn1Sbj0yvjJfR_7Cb9wbb4-DYoL74uJuMPiPu2Eg
CitedBy_id	crossref_primary_10_1007_s00604_020_4156_4 crossref_primary_10_1136_bmjopen_2024_090631 crossref_primary_10_3389_fonc_2019_00909 crossref_primary_10_1002_ijc_33204 crossref_primary_10_1016_j_radi_2023_06_010 crossref_primary_10_3390_ijms19123854 crossref_primary_10_1136_bmj_l803 crossref_primary_10_14309_ctg_0000000000000243 crossref_primary_10_1186_s40880_019_0368_6 crossref_primary_10_1002_ijgo_13458 crossref_primary_10_1089_jwh_2019_8258 crossref_primary_10_1093_annonc_mdz051 crossref_primary_10_1002_ijc_34494 crossref_primary_10_1002_bies_201900122 crossref_primary_10_1016_j_jcpo_2018_07_001 crossref_primary_10_3389_fmed_2025_1580665 crossref_primary_10_1002_1878_0261_12432 crossref_primary_10_1002_ijc_32195 crossref_primary_10_1093_eurpub_ckaf066 crossref_primary_10_1016_j_annonc_2021_12_007 crossref_primary_10_1097_CEJ_0000000000000426 crossref_primary_10_1186_s12885_021_08100_3 crossref_primary_10_5812_jamm_120371 crossref_primary_10_1002_ijc_32885 crossref_primary_10_1016_j_jcpo_2018_09_001 crossref_primary_10_1016_S2468_2667_24_00218_4 crossref_primary_10_3390_cancers13071578 crossref_primary_10_1080_0284186X_2020_1764095 crossref_primary_10_1093_jnci_djab125 crossref_primary_10_1007_s00330_021_08129_9 crossref_primary_10_1038_s41591_023_02315_6 crossref_primary_10_1136_bmjopen_2018_025109 crossref_primary_10_3390_cancers12030556 crossref_primary_10_3390_cancers13051101 crossref_primary_10_1038_s41598_024_71735_2 crossref_primary_10_1080_07853890_2025_2534098 crossref_primary_10_1080_0284186X_2019_1615637 crossref_primary_10_1016_j_jcpo_2023_100464 crossref_primary_10_7759_cureus_79274 crossref_primary_10_1016_j_ypmed_2023_107615 crossref_primary_10_1093_jjco_hyz161 crossref_primary_10_1016_j_dld_2021_03_016 crossref_primary_10_1186_s12885_018_4244_6 crossref_primary_10_1097_CEJ_0000000000000474 crossref_primary_10_1016_j_mcna_2020_08_001 crossref_primary_10_1111_cyt_13431 crossref_primary_10_1159_000536663 crossref_primary_10_1056_NEJMoa2208375 crossref_primary_10_3390_v10120729 crossref_primary_10_3390_diagnostics12061508 crossref_primary_10_1097_EE9_0000000000000182 crossref_primary_10_1158_1940_6207_CAPR_19_0192 crossref_primary_10_1016_j_gaceta_2025_102522 crossref_primary_10_1136_bmjopen_2022_062824 crossref_primary_10_1038_s41416_020_0935_2 crossref_primary_10_1007_s44266_022_00012_0 crossref_primary_10_1111_jgh_16468 crossref_primary_10_1093_eurpub_ckaf119 crossref_primary_10_1016_j_dld_2020_04_022 crossref_primary_10_1371_journal_pone_0233490 crossref_primary_10_1093_eurpub_ckad055 crossref_primary_10_1186_s13690_023_01137_9 crossref_primary_10_1186_s12905_018_0683_0 crossref_primary_10_1186_s12939_020_01275_4 crossref_primary_10_1053_j_gastro_2020_12_068 crossref_primary_10_1016_j_canep_2018_03_003 crossref_primary_10_1016_j_ijid_2020_02_051 crossref_primary_10_1016_j_jncc_2024_11_006 crossref_primary_10_1186_s12889_023_15686_9 crossref_primary_10_1053_j_gastro_2021_10_012 crossref_primary_10_1177_1403494819845565 crossref_primary_10_3390_cancers12061409 crossref_primary_10_1186_s12885_023_11583_x crossref_primary_10_7759_cureus_40540 crossref_primary_10_1016_j_annonc_2023_01_010 crossref_primary_10_3390_cancers14092343 crossref_primary_10_1002_cam4_5162 crossref_primary_10_1002_cncr_33795 crossref_primary_10_1186_s13244_020_00905_3 crossref_primary_10_1109_ACCESS_2025_3564012 crossref_primary_10_1080_14461242_2019_1601027 crossref_primary_10_1371_journal_pmed_1003431 crossref_primary_10_1016_j_bulcan_2019_03_004 crossref_primary_10_1016_j_healthpol_2020_05_011 crossref_primary_10_3389_fonc_2022_868164 crossref_primary_10_1016_j_puhe_2024_12_010 crossref_primary_10_1177_03000605251337577 crossref_primary_10_1016_j_jhealeco_2023_102803 crossref_primary_10_1002_cac2_12627 crossref_primary_10_1186_s12876_025_04213_2 crossref_primary_10_1038_s41598_021_96131_y crossref_primary_10_7717_peerj_8152 crossref_primary_10_1016_j_breast_2021_02_006 crossref_primary_10_1002_ijc_31629 crossref_primary_10_1016_j_lana_2021_100084 crossref_primary_10_1016_j_ctarc_2025_100866 crossref_primary_10_1016_j_ejca_2021_11_008 crossref_primary_10_1002_ijc_35263 crossref_primary_10_1002_ijc_34455 crossref_primary_10_1128_JCM_01176_18 crossref_primary_10_3389_fpubh_2022_862165 crossref_primary_10_1016_j_ejrad_2019_08_005 crossref_primary_10_1016_j_puhe_2018_12_007 crossref_primary_10_1002_cac2_12197 crossref_primary_10_1016_j_ypmed_2022_107229 crossref_primary_10_1093_aje_kwab254 crossref_primary_10_1002_ijc_31630 crossref_primary_10_1016_j_ijnurstu_2019_103401 crossref_primary_10_1016_S2468_1253_19_30147_5 crossref_primary_10_1111_phn_12842 crossref_primary_10_1371_journal_pone_0287486 crossref_primary_10_1590_0102_311xpt139723 crossref_primary_10_1002_ijc_32968 crossref_primary_10_1136_bmjopen_2023_079921 crossref_primary_10_1186_s12913_023_10327_8 crossref_primary_10_1136_gutjnl_2020_322192 crossref_primary_10_1186_s12889_019_7846_2 crossref_primary_10_1016_j_ejca_2018_09_001 crossref_primary_10_1053_j_gastro_2020_03_063 crossref_primary_10_1056_NEJMp2113332 crossref_primary_10_1093_jbi_wbae091 crossref_primary_10_1177_09691413251320572 crossref_primary_10_1186_s12916_022_02291_7 crossref_primary_10_1002_cam4_3857 crossref_primary_10_1016_j_puhe_2024_04_036 crossref_primary_10_1186_s12885_018_5125_8 crossref_primary_10_1002_ijc_34638 crossref_primary_10_3389_ijph_2025_1608183 crossref_primary_10_1016_j_medp_2025_100082 crossref_primary_10_1016_j_socscimed_2022_115371 crossref_primary_10_1186_s12905_021_01204_9 crossref_primary_10_2196_17430 crossref_primary_10_3390_cancers13071520 crossref_primary_10_3390_cancers16061191 crossref_primary_10_1016_j_jcpo_2024_100499 crossref_primary_10_1002_1878_0261_12459 crossref_primary_10_3748_wjg_v25_i21_2565 crossref_primary_10_7759_cureus_37989 crossref_primary_10_1097_CEJ_0000000000000603 crossref_primary_10_1016_S2468_1253_22_00084_X crossref_primary_10_1016_j_cmi_2019_09_006 crossref_primary_10_1136_gutjnl_2018_317293 crossref_primary_10_1002_ijgo_13486 crossref_primary_10_1016_j_dld_2024_11_027 crossref_primary_10_1007_s10389_023_02088_9 crossref_primary_10_1016_j_healthpol_2018_08_005 crossref_primary_10_1186_s12885_019_5647_8 crossref_primary_10_1016_j_ejca_2019_12_013 crossref_primary_10_1186_s12889_025_22535_4 crossref_primary_10_1371_journal_pone_0231422 crossref_primary_10_1055_s_0039_1698772 crossref_primary_10_1002_jmri_28495 crossref_primary_10_1007_s00103_018_2833_9 crossref_primary_10_1177_0969141319871977 crossref_primary_10_3389_fpubh_2023_1112172 crossref_primary_10_1177_0969141318820362 crossref_primary_10_1002_ijc_31372 crossref_primary_10_1002_ijc_31371 crossref_primary_10_1016_j_ejca_2019_12_010 crossref_primary_10_1371_journal_pone_0225667
Cites_doi	10.1016/j.ejca.2012.12.027 10.1016/j.ejca.2014.10.022 10.1136/bmj.38153.491887.7C 10.1016/j.canep.2015.10.021 10.1016/j.ejca.2011.06.051 10.1258/096914107781261936 10.1016/j.canep.2015.05.009
ContentType	Journal Article
Copyright	2017 UICC 2017 UICC.
Copyright_xml	– notice: 2017 UICC – notice: 2017 UICC.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8
DOI	10.1002/ijc.31043
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic
DatabaseTitleList	CrossRef AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-0215
EndPage	56
ExternalDocumentID	28940326 10_1002_ijc_31043 IJC31043
Genre	article Journal Article
GrantInformation_xml	– fundername: European Union Public Health Programme (Scientific and technical support to the European Partnership for Action against Cancer and follow‐up of the implementation of the Council Recommendation on Cancer Screening) – fundername: World Health Organization grantid: 001
GroupedDBID	--- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT .55 .GJ .Y3 31~ 3O- 53G 8WZ A6W AAMMB AANHP AAYXX ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AHEFC AI. AIDQK AIDYY AIQQE ASPBG AVWKF AZFZN BDRZF CITATION EX3 FEDTE GLUZI HF~ HVGLF M6P O8X PALCI RJQFR SAMSI VH1 WOW X7M Y6R ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8
ID	FETCH-LOGICAL-c4073-f55b03103d96af95afb7ff8b39ccf46a2aa6b6ad31203c8ca650f4acb966e0313
IEDL.DBID	DRFUL
ISSN	0020-7136 1097-0215
IngestDate	Thu Jul 10 19:02:01 EDT 2025 Tue Oct 07 05:51:01 EDT 2025 Mon Jul 21 06:04:03 EDT 2025 Tue Nov 18 21:55:11 EST 2025 Sat Nov 29 03:46:17 EST 2025 Wed Jan 22 17:08:33 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	breast cancer cancer screening colorectal cancer European Union cervical cancer
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor 2017 UICC.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4073-f55b03103d96af95afb7ff8b39ccf46a2aa6b6ad31203c8ca650f4acb966e0313
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-2423-0225 0000-0003-0124-4050 0000-0003-3016-1131
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.31043
PMID	28940326
PQID	1960968716
PQPubID	105430
PageCount	13
ParticipantIDs	proquest_miscellaneous_1942704162 proquest_journals_1960968716 pubmed_primary_28940326 crossref_citationtrail_10_1002_ijc_31043 crossref_primary_10_1002_ijc_31043 wiley_primary_10_1002_ijc_31043_IJC31043
PublicationCentury	2000
PublicationDate	1 January 2018
PublicationDateYYYYMMDD	2018-01-01
PublicationDate_xml	– month: 01 year: 2018 text: 1 January 2018 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Hoboken
PublicationTitle	International journal of cancer
PublicationTitleAlternate	Int J Cancer
PublicationYear	2018
Publisher	Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc
References	2015; 39 2013; 49 2010 2015; 51 2008 2017 2006 2015 2003 2014 2012; 48 2013 2004; 329 2007; 14 e_1_2_8_17_1 e_1_2_8_18_1 Segnan N (e_1_2_8_11_1) 2010 e_1_2_8_13_1 e_1_2_8_15_1 e_1_2_8_16_1 WHO (e_1_2_8_19_1) 2014 Anttila A (e_1_2_8_10_1) 2015 Martin‐Moreno JM (e_1_2_8_14_1) 2013 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 Arbyn M (e_1_2_8_9_1) 2008 e_1_2_8_7_1 EUROSTAT (e_1_2_8_12_1) 2015 e_1_2_8_6_1 WHO (e_1_2_8_20_1) 2014 e_1_2_8_8_1 29732546 - Int J Cancer. 2018 Jul 1;143(1):E1. doi: 10.1002/ijc.31359. 29642254 - Z Gastroenterol. 2018 Apr;56(4):401-403. doi: 10.1055/s-0044-102024.
References_xml	– volume: 39 start-page: S1 year: 2015 end-page: 10 article-title: European code against Cancer 4th Edition: 12 ways to reduce your cancer risk publication-title: Cancer Epidemiol – volume: 48 start-page: 743 year: 2012 end-page: 8 article-title: Determinants of successful implementation of population‐based cancer screening programmes publication-title: Eur J Cancer – volume: 14 start-page: 81 year: 2007 end-page: 6 article-title: Lessons learnt from a population‐based pilot programme for colorectal cancer screening in Catalonia (Spain) publication-title: J Med Screen – year: 2008 – year: 2006 – year: 2003 – volume: 49 start-page: 1374 year: 2013 end-page: 403 article-title: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 publication-title: Eur J Cancer – year: 2017 – volume: 51 start-page: 241 year: 2015 end-page: 51 article-title: Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries publication-title: Eur J Cancer – volume: 39 start-page: S139 year: 2015 end-page: 52 article-title: European Code against Cancer, 4th Edition: Cancer screening publication-title: Cancer Epidemiol – year: 2014 – year: 2015 – year: 2010 – year: 2013 – volume: 329 start-page: 133 year: 2004 article-title: Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom publication-title: BMJ – ident: e_1_2_8_5_1 – volume-title: Boosting Innovation and Cooperation in European Cancer Control: key Findings from the European Partnership for Action against Cancer year: 2013 ident: e_1_2_8_14_1 – ident: e_1_2_8_2_1 doi: 10.1016/j.ejca.2012.12.027 – ident: e_1_2_8_6_1 – volume-title: European Guidelines for Quality Assurance in Cervical Cancer Screening year: 2015 ident: e_1_2_8_10_1 – ident: e_1_2_8_17_1 doi: 10.1016/j.ejca.2014.10.022 – volume-title: Comprehensive Cervical Cancer Control ‐ a Guide to Essential Practice year: 2014 ident: e_1_2_8_20_1 – volume-title: European Guidelines for Quality Assurance in Cervical Cancer Screening year: 2008 ident: e_1_2_8_9_1 – volume-title: Eurostat Regional Yearbook 2015 year: 2015 ident: e_1_2_8_12_1 – ident: e_1_2_8_8_1 – ident: e_1_2_8_18_1 – ident: e_1_2_8_16_1 doi: 10.1136/bmj.38153.491887.7C – ident: e_1_2_8_4_1 doi: 10.1016/j.canep.2015.10.021 – volume-title: European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis year: 2010 ident: e_1_2_8_11_1 – ident: e_1_2_8_13_1 doi: 10.1016/j.ejca.2011.06.051 – ident: e_1_2_8_15_1 doi: 10.1258/096914107781261936 – ident: e_1_2_8_3_1 doi: 10.1016/j.canep.2015.05.009 – ident: e_1_2_8_7_1 – volume-title: WHO Position Paper on Mammography Screening year: 2014 ident: e_1_2_8_19_1 – reference: 29642254 - Z Gastroenterol. 2018 Apr;56(4):401-403. doi: 10.1055/s-0044-102024. – reference: 29732546 - Int J Cancer. 2018 Jul 1;143(1):E1. doi: 10.1002/ijc.31359.
SSID	ssj0011504
Score	2.6040275
Snippet	The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	44
SubjectTerms	Age Breast cancer Breast Neoplasms - diagnosis Cancer Cancer screening Cervical cancer Cervix Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - diagnosis Early Detection of Cancer - statistics & numerical data European Union Female Humans Male Mammography Mass Screening - organization & administration Mass Screening - statistics & numerical data Medical research Medical screening Surveys and Questionnaires Uterine Cervical Neoplasms - diagnosis
Title	Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.31043 https://www.ncbi.nlm.nih.gov/pubmed/28940326 https://www.proquest.com/docview/1960968716 https://www.proquest.com/docview/1942704162
Volume	142
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011504 issn: 0020-7136 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7BglAv0PIoW7bIRRy4RIQ4D684oYVVQQVVPKS9RbZjS1vRLNrs9twfwZU_xy_pTJxkQYCE1FukjGPLnrG_z46_Adi1JkuyxIRISyT3cL3VnlA68oQMImETaWMtymQTycWFGAy6P-fgsL4L4_Qhmg03ioxyvqYAl6rYn4mGDn9pJJx-yOdhIUC_jVqwcHzZv_nRHCIg1qlEmH0PuVhcCwv5wX5T-Ply9AJjPoes5ZrTX_mv1n6E5QpqsiPnG59gzuSrsHReHaavwQMBzWnBRpYNf9e_kdM4MZlnbPTkkiaZaHKPMcNZBpkvrndsmDP0MVZv5zNEr2h5bijDCHMY9vHv_ZW7HMeQ1U9vJwWj6ywMQScriIlns-KzD7tjjHW46Z9c9757VbYGTyMp5J6NIkU6ozzrxtJ2I2lVYq1QvKu1DWMZSBmrWGb8IPC5FloiNrSh1AoJlyEFyQ1o5aPcbAKTItIy5GhuFNJHrjJym0SpwCAaVLYNe_WgpbqSMqeMGrepE2EOUuzutOzuNuw0pndOv-M1o0498mkVwkV6QFp8MfHJNnxrXmPw0YmKzM1oSjYhuh5i2qANn53HNLUgkw19BMfY2NIx3q4-PT3rlQ9f3m-6BR8Qugm3GdSB1mQ8NV9hUf-ZDIvxNswnA7FdxcM_ADUQ8w
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7xEnBpoUC7lIKpOHCJCHEeXqmXCrrisbtCLUjcItuxpUU0W212OfMjuPbP9ZcwEydZUFsJiVukjGPLnrG_bxx_BtizJkuyxIRISyT3cL3VnlA68oQMImETaWMtyssmkn5fXF-3L2bgS30WxulDNAk3ioxyvqYAp4T0wVQ1dHCjkXH6IZ-F-RDdCP17_vh756rb7CIg2KlUmH0PyVhcKwv5wUFT-Pl69BfIfI5Zy0Wn8_Z1zV2BNxXYZF-dd6zCjMnfwWKv2k5fg98ENScFG1o2-Fn_SE4jxWSeseGTY5pkoslBRgznGeS-uOKxQc7Qy1id0GeIX9GyZ-iOEeZQ7J_7hx_ueBxDXj-5HReMDrQwhJ2sIC6eTYtPP-w2MtbhqvPt8ujEq-5r8DTSQu7ZKFKkNMqzdixtO5JWJdYKxdta2zCWgZSximXGDwOfa6ElokMbSq2QchnSkNyAuXyYmw_ApIi0DDmaG4UEkquMHCdRKjCIB5VtwX49aqmuxMzpTo3b1MkwByl2d1p2dws-N6a_nILHv4y26qFPqyAu0kNS44uJUbZgt3mN4Ud7KjI3wwnZhEHiI6oNWvDeuUxTC3LZ0Ed4jI0tPeP_1aenZ0flw-bLTXdg6eSy1027p_3zj7CMQE641NAWzI1HE_MJFvTdeFCMtquweATVQRP7
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3RBSEuQGmBBdoaxIFLRIjz4ZW4VNBV-VohChK3yHZsaRFk0WaXMz-i1_45fgkzcZItKpWQuEXKOLbsGfs9O34DsG1NlmSJCZGWSO7heqs9oXTkCRlEwibSxlqUySaSXk9cX3fOp2C_vgvj9CGaDTeKjHK-pgA395ndnaiG9m80Mk4_5B9gOqQkMi2YPrzoXp02pwgIdioVZt9DMhbXykJ-sNsUfrke_QMyX2LWctHpLryvuYswX4FN9t15x0eYMvkSzJ5Vx-mf4A9BzXHBBpb17-ofyWmkmMwzNvjrmiaZaHKQIcN5BrkvrnisnzP0MlZv6DPEr2h5ZijHCHMo9unx9y93PY4hrx_fjgpGF1oYwk5WEBfPJsUnH3YHGZ_hqvvj8uCnV-Vr8DTSQu7ZKFKkNMqzTixtJ5JWJdYKxTta2zCWgZSximXG9wKfa6ElokMbSq2QchnSkFyGVj7IzSowKSItQ47mRiGB5Cojx0mUCgziQWXbsFOPWqorMXPKqXGbOhnmIMXuTsvubsNWY3rvFDxeM9qohz6tgrhI90iNLyZG2YbN5jWGH52pyNwMxmQTBomPqDZow4pzmaYW5LKhj_AYG1t6xv-rT4-OD8qHtbebfoPZ88NuenrUO1mHOcRxwu0MbUBrNBybLzCjH0b9Yvi1iopnRSQTdg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Status+of+implementation+and+organization+of+cancer+screening+in+The+European+Union+Member+States%E2%80%94Summary+results+from+the+second+European+screening+report&rft.jtitle=International+journal+of+cancer&rft.au=Basu%2C+Partha&rft.au=Ponti%2C+Antonio&rft.au=Anttila%2C+Ahti&rft.au=Ronco%2C+Guglielmo&rft.date=2018-01-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=142&rft.issue=1&rft.spage=44&rft.epage=56&rft_id=info:doi/10.1002%2Fijc.31043&rft.externalDBID=10.1002%252Fijc.31043&rft.externalDocID=IJC31043
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon